Center of Research on Obesity and Cardiovascular Disease

肥胖与心血管疾病研究中心

• 批准号: 9982352
• 负责人: Lisa A Cassis
• 金额: $ 114.75万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9982352
• 关键词: Adipose tissue; Advisory Committees; Aging; Alzheimer' s Disease; Area; Award; Basic Science; Body Composition; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Centers of Research Excellence; Chronic Disease; Clinical Research; Clinical Sciences; Core Facility; Death Rate; Development; Diabetes Mellitus; Diet; Disease; Equipment; Etiology; Evaluation; Extramural Activities; Fostering; Funding; Gills; Goals; Growth; High Prevalence; Hypertension; Infrastructure; Institutes; Institution; Kentucky; Limb structure; Link; Lipids; Malignant Neoplasms; Mass Spectrum Analysis; Mentors; Morphology; Mus; Neurodegenerative Disorders; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathology; Phase; Physicians; Pilot Projects; Prevalence; Publications; Publishing; Request for Applications; Research; Research Infrastructure; Research Personnel; Research Support; Risk; Risk Factors; Scientist; Services; Strategic Planning; System; Technology; Tissues; Translating; Translational Research; United States National Institutes of Health; Universities; cancer research center director; cardiovascular risk factor; clinical care; clinical center; comorbidity; energy balance; experience; health disparity; human disease; improved; obesity development; programs; research facility; small molecule; success; targeted treatment; therapy development; voucher

Phase III of the Center for Biomedical Research Excellence (COBRE) on Obesity and Cardiovascular Diseases (COCVD) will further develop and expand upon obesity as an underlying risk factor for the development of cardiovascular diseases, type 2 diabetes, cancer and neurodegenerative diseases. Each of these diseases are rampant in Kentucky, and obesity has been identified as a contributing risk factor for each condition. For Phase III of the COCVD, we will transition the research core facilities developed during Phase I and II of this program to independence. We will also support pilot project studies that include obesity as a risk factor for disease development. We have experienced considerable success, having supported 23 junior investigators and 21 pilot project investigators who generated $52 million in extramural funding and published more than 500 scholarly publications. Collectively, our team has published more than 280 scholarly articles that directly cite COCVD support. We developed an analytical core that provides services in lipidomics and other small molecules, a pathology core that provides specialized services to quantify adipose and other tissue morphology, and an energy balance and body composition core that is not duplicated in capacity across the institution or the Commonwealth. During Phase III of the COCVD, we will transition each core to self- sustaining capacity and upgrade core equipment and use by continuing to provide high quality specialized services, and by expanding core capabilities through provision of additional services that relate obesity to other diseases (e.g., cancer). Transition to independence of COCVD cores will be facilitated by use of a voucher system to promote core use. We will also continue our strong tradition of pilot project funding, which will be expanded to include studies that focus on obesity as an underlying risk factor for not only cardiovascular diseases, but also type 2 diabetes, cancer and neurodegenerative diseases. These areas have been designated as areas of strength across the institution (as each disease is a health disparity experienced by Kentuckians), and are designated for growth within a new research facility that will focus on Kentucky's health disparities. The Administrative Core will oversee all administrative functions of the COCVD and in conjunction with the Program Coordinator and the Scientific Internal Advisory Committee will serve as the operational limb of the Center. An External Advisory Committee, composed of experts in related fields, will provide ongoing assessment and evaluation of the Center. Institutional commitment continues to be outstanding and is supplemented by strong evidence of programmatic growth of direct relevance to this Phase III COCVD.

肥胖和心血管生物医学研究卓越中心(COBRE)第三阶段 疾病(COCVD)将在肥胖的基础上进一步发展和扩大，成为 心血管疾病、2型糖尿病、癌症和神经退行性疾病的发展。每一个 这些疾病在肯塔基州很猖獗，肥胖已被确定为每种疾病的致病风险因素 条件。至于第三阶段，我们会把第一阶段发展的研究核心设施 和这个节目的二号走向独立。我们还将支持将肥胖作为风险因素的试点项目研究 疾病发展的因素。我们经历了相当大的成功，已经资助了23名少年 调查人员和21名试点项目调查人员，他们获得了5200万美元的外部资金，并发布了 超过500种学术出版物。我们的团队总共发表了280多篇学术文章 直接引用了对COCVD的支持。我们开发了一种分析核心，提供脂类组学和 其他小分子，提供量化脂肪和其他组织的专门服务的病理核心 形态，以及能量平衡和身体组成核心，在能力上不会在整个 机构或英联邦。在COCVD的第三阶段，我们将每个核心过渡到自我 通过继续提供高质量的专业技术来维持能力和升级核心设备和使用 服务，并通过提供与其他肥胖相关的额外服务来扩展核心能力 疾病(如癌症)。通过使用凭单，将促进COCVD核心向独立的过渡 促进核心使用的系统。我们还将继续我们为试点项目提供资金的强大传统，这将是 扩大到包括关注肥胖不仅是心血管疾病的潜在风险因素的研究 疾病，但也有2型糖尿病、癌症和神经退行性疾病。这些地区一直是 被指定为整个机构的优势领域(因为每种疾病都是 肯塔基州)，并被指定在一个新的研究机构内增长，该机构将专注于肯塔基州的健康 差距。行政核心将监督COCVD的所有行政职能，并与 方案协调员和科学内部咨询委员会将作为业务分支 中心的一部分。由相关领域的专家组成的外部咨询委员会将持续提供 对该中心的评估和评价。机构承诺继续突出，并正在 并辅之以与第三阶段气候变化和气候变化直接相关的方案增长的有力证据。